Previous 10 | Next 10 |
Search all stock news releases related news releases and press releases from US and Canada Markets.
Presentations include new data further demonstrating the immune responses induced by TG4001 and recently updated results from the adjuvant Phase I trial of neoantigen vaccine TG4050 in head and neck cancer Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that desi...
Presentations include new data further demonstrating the immune responses induced by TG4001 and recently updated results from the adjuvant Phase I trial of neoantigen vaccine TG4050 in head and neck cancer Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that desi...
GENEVA, SWITZERLAND / ACCESSWIRE / May 26, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFFD )(OTCQB: RLFTD ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to b...
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma TOKYO, May 26, 2023 - (JCN Newswire) - Eisai and Merck & Co., Inc., Rahway, NJ, USA (known...
The ‘Coming To A Storm Near You’ launch was the second of two dedicated Electron launches to deploy a constellation of hurricane monitoring satellites for NASA Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a leading launch...
SAR’579/IPH6101, ANKET ® platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi Preliminary data published show SAR’579 was ...
SAR’579/IPH6101, ANKET ® platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi Preliminary data published show SAR’579 was ...
– If Granted by the European Commission, Veklury will become the First and Only Authorized Antiviral Treatment Across All Stages of Renal Disease – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Sydney, Australia (ABN Newswire) - Magnis Energy Technologies Limited (ASX:MNS) (FRA:U1P) (OTCMKTS:MNSEF) is pleased to announce the appointment of Non-Executive Director Hoshi Daruwalla as the Company's Managing Director (USA). Based in the United States, Hoshi will oversee Magnis' U.S. expansio...
Brisbane, Australia (ABN Newswire) - North American lithium producer Sayona Mining Limited (ASX:SYA) (FRA:DML) (OTCMKTS:SYAXF) has secured additional funding to speed development of its Quebec lithium resources, with the launch of a fully underwritten A$200 million two tranche placement (Placemen...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
17.2%Change Percent:
Pactiv Evergreen Inc. Company Name:
PTVE Stock Symbol:
NASDAQ Market:
pactivevergreen.com Website: